CSPC PHARMA (01093) subsidiary receives US$15 million development milestone payment under the exclusive license agreement with CORBUS PHARMACEUTICALS for CRB-701 (SYS 6002)

date
17:17 19/11/2026
avatar
GMT Eight
CSPC PHARMA (01093) announced that, in relation to the exclusive license agreement entered into between the Company's subsidiary CSPC Megalith Biopharmaceutical Co., Ltd. (Megalith Bio) and Corbus Pharmaceuticals Inc. (Corbus Pharmaceuticals) for CRB-701 (SYS 6002)
CSPC PHARMA (01093) announced that, in relation to the exclusive license agreement entered into between the Company's subsidiary CSPC PHARMA Megalith Biopharmaceutical Co., Ltd. (Megalith Biopharmaceutical) and Corbus Pharmaceuticals Inc. (Corbus Pharmaceuticals) for CRB-701 (SYS 6002), Megalith Biopharmaceutical received a US$15 million development milestone payment from Corbus Pharmaceuticals on November 18, 2026. As of the date of this announcement, Megalith Biopharmaceutical has cumulatively received an aggregate of US$32.5 million in upfront and development milestone payments from Corbus Pharmaceuticals under the agreement. The achievement of this milestone marks that the relevant research and development work under the agreement is progressing steadily as planned.